Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy
Esther Natalie Olíva(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Maria Antonietta Aloe Spiriti(Sapienza University of Rome), Enrico Balleari(Ospedale Policlinico San Martino), Roberto Latagliata(Ospedale di Belcolle), Fortunato Morabito(Azienda Ospedaliera di Cosenza), Grazia Sanpaolo(Casa Sollievo della Sofferenza), Francesco Nobile(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Filippo Rodà(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Maria Grazia D’Errigo(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Giorgina Specchia(Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari), Giuseppe A. Palumbo(University of Catania), Carmelo Laganà(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Carlo Finelli(Azienda USL di Bologna), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Antonella Poloni(Marche Polytechnic University), Massimo Breccia(Policlinico Umberto I), Caterina Alati(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Antonio Volpe(Azienda Ospedaliera S.Giuseppe Moscati), Giuliana Alimena(Thrombolysis in Myocardial Infarction Study Group), Sara Galimberti(University of Pisa)
Cited by 30
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464